Literature DB >> 8704177

Telomerase activation in normal B lymphocytes and non-Hodgkin's lymphomas.

K F Norrback1, K Dahlenborg, R Carlsson, G Roos.   

Abstract

Activation of telomerase seems to be a prerequisite for immortalization and is found in permanent cell lines and most malignant tumors. Normal somatic cells are generally telomerase negative, except for bone marrow stem cells. Weak activity is also present in peripheral blood cells. In the present study strong telomerase activity was demonstrated in vivo in normal mature cells of the immune system, as well as in malignant lymphomas. Benign lymph nodes had lower telomerase activity than benign tonsils, which exhibited intermediate to high activity comparable with findings in malignant lymphomas. In benign tonsils the activity seemed to be restricted to germinal center B cells. In benign lymphoid tissues telomerase activity correlated with B-cell numbers and cell proliferation, but this was not observed in the lymphoma group. High-grade lymphomas exhibited higher levels of telomerase compared with low-grade cases. The data showed that in vivo activation of telomerase is a characteristic feature of germinal center B cells. Different signals for activation of telomerase are likely to exist, one of them being immune stimulation. The data suggest that telomerase activity in malignant lymphomas can be explained by an "induction and retention" model, ie, transformation occurs in a normal, mature B cell with reactivated telomerase, which is retained in the neoplastic clone.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8704177

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

1.  Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes.

Authors:  K Liu; M M Schoonmaker; B L Levine; C H June; R J Hodes; N P Weng
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

Review 2.  The role of telomerase expression and telomere length maintenance in human and mouse.

Authors:  N P Weng; R J Hodes
Journal:  J Clin Immunol       Date:  2000-07       Impact factor: 8.317

3.  Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes.

Authors:  Enrica Rampazzo; Laura Bonaldi; Livio Trentin; Carlo Visco; Sonia Keppel; Silvia Giunco; Federica Frezzato; Monica Facco; Elisabetta Novella; Ilaria Giaretta; Paola Del Bianco; Gianpietro Semenzato; Anita De Rossi
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

4.  Impaired germinal center reaction in mice with short telomeres.

Authors:  E Herrera; C Martínez-A; M A Blasco
Journal:  EMBO J       Date:  2000-02-01       Impact factor: 11.598

5.  Change of telomerase activity in peripheral whole blood of head and neck squamous cell carcinoma patients before and after surgery: a pilot study.

Authors:  Y S Lee; K Tae; S H Lee; S H Cho; J H Jeong; H J Min; Y B Ji
Journal:  Clin Transl Oncol       Date:  2011-10       Impact factor: 3.405

Review 6.  Common mechanisms for the regulation of B cell differentiation and transformation by the transcriptional repressor protein BCL-6.

Authors:  Saritha Kusam; Alexander Dent
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 7.  Telomere and adaptive immunity.

Authors:  Nan-ping Weng
Journal:  Mech Ageing Dev       Date:  2007-12-08       Impact factor: 5.432

8.  HHV-8 is not associated with follicular dendritic cell tumours.

Authors:  S J Nayler; L Taylor; K Cooper
Journal:  Mol Pathol       Date:  1998-06

9.  Telomere lengthening and telomerase activation during human B cell differentiation.

Authors:  N P Weng; L Granger; R J Hodes
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

Review 10.  Telomerase activity, cell proliferation, and cancer.

Authors:  C W Greider
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.